Conditions: Prostate Cancer
Keywords: African American men metastatic prostate cancer castration resistant
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 11
Healthy volunteers: no

Brief summary:
This is a pilot study of abiraterone acetate in African American/Black patients with castration-resistant prostate cancer. The primary objective is to determine the correlation between germline polymorphisms and antitumor activity (as defined by a decline in PSA of ≥ 30%) in African American patients with castration-resistant prostate cancer treated with abiraterone acetate. Patients will receive abiraterone acetate until the time of disease progression, in the absence of prohibitive toxicities. Patients will be followed for disease progression and survival.

Detailed description:

Arms:
arm 1: Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.

Interventions: intervention 1: Abiraterone Acetate
Intervention descriptions: intervention 1: Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily

Protocol document: